Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2004 6
2006 1
2010 2
2012 1
2017 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.
Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F, Mainwaring P, Harland S, Goodman OB Jr, Sternberg CN, Li JH, Kheoh T, Haqq CM, de Bono JS; COU-AA-301 Investigators. Fizazi K, et al. Lancet Oncol. 2012 Oct;13(10):983-92. doi: 10.1016/S1470-2045(12)70379-0. Epub 2012 Sep 18. Lancet Oncol. 2012. PMID: 22995653 Clinical Trial.
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A; ExteNET Study Group. Martin M, et al. Lancet Oncol. 2017 Dec;18(12):1688-1700. doi: 10.1016/S1470-2045(17)30717-9. Epub 2017 Nov 13. Lancet Oncol. 2017. PMID: 29146401 Clinical Trial.
[Pharmaceutical therapy of breast cancer].
Láng I, Kahán Z, Pintér T, Dank M, Boér K, Pajkos G, Faluhelyi Z, Pikó B, Eckhardt S, Horváth Z. Láng I, et al. Among authors: faluhelyi z. Magy Onkol. 2010 Sep;54(3):237-54. doi: 10.1556/MOnkol.54.2010.3.5. Magy Onkol. 2010. PMID: 20870601 Free article. Hungarian. No abstract available.
Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial.
Ocvirk J, Brodowicz T, Wrba F, Ciuleanu TE, Kurteva G, Beslija S, Koza I, Pápai Z, Messinger D, Yilmaz U, Faluhelyi Z, Yalcin S, Papamichael D, Wenczl M, Mrsic-Krmpotic Z, Shacham-Shmueli E, Vrbanec D, Esser R, Scheithauer W, Zielinski CC. Ocvirk J, et al. Among authors: faluhelyi z. World J Gastroenterol. 2010 Jul 7;16(25):3133-43. doi: 10.3748/wjg.v16.i25.3133. World J Gastroenterol. 2010. PMID: 20593498 Free PMC article. Clinical Trial.
Early effects of transplatin on oncogene activation in vivo.
Németh A, Nádasi E, Beró A, Olasz L, Ember A, Kvarda A, Bujdosó L, Arany I, Csejtei A, Faluhelyi Z, Ember I. Németh A, et al. Among authors: faluhelyi z. Anticancer Res. 2004 Nov-Dec;24(6):3997-4001. Anticancer Res. 2004. PMID: 15736445 Free article.
[Role of Caelyx in second line treatment of ovarian cancer].
Pulay T, Csömör S, Faluhelyi Z, Hernádi Z, Krommer K, Mayer A, Szánthó A, Szántó I, Thurzó L. Pulay T, et al. Among authors: faluhelyi z. Magy Onkol. 2004;48(1):97-9. Epub 2004 Apr 23. Magy Onkol. 2004. PMID: 15105903 Free article. Hungarian.
12 results